Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
12.01
-0.36 (-2.91%)
Oct 8, 2026, 11:11 AM EDT - Market open
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year. That makes Enanta Pharmaceuticals the 30,236th largest employer in the world and 3,883rd in the United States.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$543,817
Profits / Employee
-$526,917
Market Cap
349.80M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cabaletta Bio | 158 |
| Ocugen | 116 |
| Artiva Biotherapeutics | 115 |
| Arcturus Therapeutics Holdings | 111 |
| C4 Therapeutics | 104 |
| Orchestra BioMed Holdings | 86 |
| Inhibikase Therapeutics | 35 |
| Fennec Pharmaceuticals | 35 |
ENTA News
- 22 days ago - Enanta Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 22 days ago - Enanta Pharmaceuticals Transcript: 2026 Global Healthcare Conference - Transcripts
- 5 weeks ago - Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire
- 1 month ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire
- 1 month ago - Enanta Pharmaceuticals Earnings release: Q3 2026 - Filings
- 1 month ago - Enanta Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 3 months ago - Enanta announces European Commission approval of Maviret - TheFly
- 3 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - Business Wire